Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
85%
Ulcerative Colitis
43%
Tumor Necrosis Factor-α
27%
Vedolizumab
20%
Infliximab
20%
Israeli
17%
Pouch
16%
Clinical Remission
16%
Israel
15%
Ustekinumab
14%
Crohn's
14%
Newly Diagnosed
14%
Fecal Calprotectin
13%
Epi-IIRN
12%
Disease Activity
11%
Colitis
11%
Multicenter Retrospective Study
10%
Disease Course
9%
Video Capsule Endoscopy
9%
Hospitalization
8%
Moderate to Severe
8%
Ulcerative Colitis Patient
8%
Remission Induction
8%
Real-world Experience
8%
Adalimumab
8%
Hazard Ratio
7%
COVID-19
7%
Crohn's Disease Exclusion Diet
7%
95% Confidence Interval
7%
Serological Response
7%
Severe Ulcerative Colitis
7%
Disease Phenotype
7%
Magnetic Resonance Enterography
6%
Corticosteroids
6%
Capsule Endoscopy
6%
Tofacitinib
6%
Remission
6%
Ileal Pouch
6%
Prospective Cohort Study
6%
Anti-drug Antibodies
6%
Tertiary Care Centers
6%
Steroid Use
6%
Adverse Events
6%
Acute Diverticulitis
5%
Complicated Disease
5%
Active Ulcerative Colitis
5%
Mediterranean Diet Adherence
5%
Biological Therapy
5%
Endoscopy
5%
Medicine and Dentistry
Crohn's Disease
68%
Inflammatory Bowel Disease
61%
Ulcerative Colitis
33%
Diseases
29%
Patient with Inflammatory Bowel Disease
26%
Vedolizumab
18%
Tumor Necrosis Factor
18%
Biological Product
15%
Patient with Ulcerative Colitis
15%
Ustekinumab
15%
Capsule Endoscopy
14%
Patient with Crohn's Disease
14%
Faecal Calprotectin
12%
Colitis
12%
Retrospective Cohort Study
11%
Infection
9%
Pouchitis
9%
Biological Therapy
8%
Steroids
8%
Cohort Analysis
7%
Quality of Life
7%
Disease Course
7%
Infliximab
7%
Colectomy
7%
Hazard Ratio
6%
Patient Referral
6%
Magnetic Resonance Enterography
6%
Pediatrics
6%
Recurrent Disease
6%
Disease Activity
6%
Diverticulitis
5%
Elimination Diet
5%
Ileo-Anal Pouch
5%
Mediterranean Diet
5%
Tofacitinib
5%
Corticosteroid
5%
Adverse Event
5%
Inflammation
5%